Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conserved-Mosaic T-cell Vaccine, Vesatolimod, and bNAbs in Adults with HIV-1
NCT06071767Phase 2Suspended
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, vesatolimod in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2024; status: suspended.
02
Drugs
ChAdOx1.tHIVconsv1ChAdOx1.HIVconsv62MVA.tHIVconsv3MVA.tHIVconsv4vesatolimod
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06071767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071767.